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Personalized medicine, based on individuals’ genomes or
proteomes challenges conventional clinical diagnostic
categories and increases the number of “rare conditions”
which may benefit from personalized treatments. Current
drug evaluation, based on diagnostic categories ignores
the large range of phenotypic expressions; the consider-
able variation in drug responses by individuals creates
legitimate concerns regarding the efficacy and safety of
many drugs for patients. Furthermore, when diseases
affect individuals’ daily activities, standardized popula-
tion-based assessment tools lack the capacity to reliably
reflect a drug’s effects on outcomes most relevant to the
patient’s own everyday needs and perception of wellness
- the individual patient’s Personal Outcomes of Specific
Interest (“POSI”). The uniqueness of individual’s POSI
challenges the classic phase 3 trials to assess drug effects;
conversely, the validity of evaluating drug effects with
standard tools – surrogate markers of a true experience
– is questionable.
It is therefore essential to develop a new approach to
carefully assess the impact of these drugs on the out-
comes that are most important for patients while also
assessing the bio-physiological effectiveness.
In 2010, we developed a personalized medicine strategy
using a systematic consultative model of decision-making
that incorporates individual patients/families’ insights
about the impact of drugs on everyday activities and their
preferred outcomes into the treatment evaluation and
decision making process; we also developed with UBC
School of Engineering the “Wellness Tracker” (WT) soft-
ware that enables patients/families to track signs and
symptoms on a daily basis, and share this information
with caregivers (http://wellnesstracker.org), to guide thera-
peutics and decisions. WT can be used in n-of-1 clinical
trials that are the best design for assessing drug effective-
ness and side effects at individual and population levels.
The personal evaluation model (PEM) includes 4 steps
to: (i) identify POSI with the patient/family in consultation
with the physician; (ii) determine which drug effects
would make the treatment useful; (iii) assess changes in
POSI over time and scale this change using the goal
attainment scaling (GAS) technique; (iv) share this infor-
mation to the discussion with care providers to make the
most appropriate decisions regarding drug usage and
adherence considering utility scorings from the different
parties.
This approach also provides important data for policy
makers to evaluate reimbursement for expensive treat-
ments. Finally, it can also be used to study off-label appli-
cations of previously approved drugs, herbal products and
dietary supplements; most of which are never evaluated
rigorously. Presentation illustrates use of Personalized
Evaluation Model in practice.
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